ART4 and Epstein-Barr virus infection: In 2020, Escalante et al. found that a pentavalent EBV glycoprotein (gp350, gB, gp42, gH, and gL) VLP formulation induced a more efficient humoral immune response in rabbits compared to soluble gp350 extracellular domains and provided better protection against EBV infection of B and epithelial cells [178].